EU Gives Lynparza Green Light as First-Line Ovarian Cancer Treatment
The DNA damage repair drug olaparib (Lynparza), developed by AstraZeneca and Merck, has been approved…
The DNA damage repair drug olaparib (Lynparza), developed by AstraZeneca and Merck, has been approved…
Checkpoint inhibitors, especially those targeting PD-1 and PD-L1, are exploding in popularity. But how much…
Danish biotech LEO Pharma started a Phase III trial in atopic dermatitis with an antibody…
Bavarian Nordic and AstraZeneca collaborate on a treatment that uses a cancer vaccine along with…
AstraZeneca collaborates with Swedish firm Pelago Bioscience to develop assay that increases the speed and…
The FDA approval will give AstraZeneca a competitive advantage in the lung cancer treatment market over Merck…
The UK big pharma company's Lynparza will be for women with advanced breast cancer that…
AstraZeneca will work with Moderna Therapeutics to bring together to the market an mRNA version of Novartis' failed…
The PTEN gene controls cell growth and behavior, with its loss implicated in cancer. AstraZeneca…
Though the psoriasis market is teeming with effective products, companies have developed ways to devise…
UPDATE: 11/09/2017: AstraZeneca has presented impressive results at ESMO that show Imfinzi adding 11 months…
Circassia has positive Phase III results from its respiratory pipeline, great news for the company…